Wed, 5th November, 2025
5:00pm CET / 8:00am PST
Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative, especially to manufacture large quantities, is the enzymatic ligation of short oligonucleotide fragments. This approach offers several advantages compared to the conventional strategy like higher yields and reduced purification burdens. Bachem and Codexis will present a case study focusing on a therapeutically relevant siRNA sequence and benchmark different technologies used to manufacture siRNA fragments. We will discuss a holistic view of the manufacturing process and review control strategies for residual enzymes.
Speaker Bios
Mathias Beysard, PhD
Business Development Manager Oligo
Bachem
Mathias Beysard is a Business Development Manager for oligonucleotides at Bachem, with a strong background in molecular biology and commercial strategy. Mathias holds a PhD in Natural Sciences from the University of Bern. Prior to joining Bachem, Mathias spent nearly a decade at Microsynth, where he served as Sales Manager and later Head of Sales. During this time, he played a pivotal role in growing the company’s oligonucleotide business, particularly in the diagnostics and research sectors.
Mathew Miller
Director, Life Science & RNA Technologies
Codexis
Mathew Miller joined Codexis in 2009, and has worked on enzyme engineering projects including T7 RNA polymerases for mRNA manufacturing, enzymatic oligo synthesis, and RNA ligation technologies. He is currently focused on enzymatic routes for siRNA synthesis. Dr. Miller received his Ph.D. from the University of California, San Francisco.
Benjamin Breitenbach, PhD
Senior Group Leader Oligo R&D I
Bachem
Benjamin Breitenbach earned his Ph.D. in Polymer guided drug delivery from Johannes Gutenberg University Mainz in 2019. He then joined Ascendis Pharma as a Bench Scientist, focusing on biopolymer hydrogel chemistry. In 2021, Benjamin joined Bachem as a group leader in Oligo Production I, later in Oligo R&D I and since October 2024, he is serving as Senior Group Leader in Oligo R&D I, driving innovation in oligonucleotide development and production.
Link for subscription: https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/